GigaMedia (NASDAQ:GIGM) reported quarterly losses of $(0.10) per share. This is a 25 percent decrease over losses of $(0.08) per share from the same period last year.
Astellas Pharma Licenses Promising Gene Therapy KT430 from Kate Therapeutics Amidst Clinical Hurdles
Astellas Pharma Inc (OTC: ALPMF) (OTC: ALPMY) decided to license and advance a gene therapy from Kate Therapeutics for a debilitating muscle disorder known as
